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Abstract 
Background: Past studies have reported conflicting results regarding the association between 
acetaminophen use during pregnancy and the risk of developing childhood asthma. 
Objectives: To perform an updated review on past studies investigating the association between 
prenatal acetaminophen use and the risk of developing asthma within the first ten years of life. 
Methods: A systematic review and meta-analysis was conducted using PubMed search (1950-
December 1, 2011) to identify studies that investigated the association between intrauterine 
exposure to acetaminophen and childhood asthma. Inclusion criteria consisted of a study design 
restricted to prospective cohort studies, primary exposure of acetaminophen intake during 
pregnancy, and primary outcome of physician-diagnosed asthma or a combination of two of the 
following indicators of asthma (use of asthma medication, hospitalization due to asthmatic 
symptoms, wheezing, and ER visits due to wheezing). Study quality was assessed and data was 
extracted by one reviewer. An inverse variance fixed-effects model was used, and adjusted odds 
ratio was calculated to compare effect sizes of studies.  
Results: The review comprised of six studies: two studies assessed physician-diagnosed asthma 
among children under the age of 2 years and four studies ascertained asthma outcome between the 
ages 2 and 10 years.  The overall pooled estimate calculated from all six studies was 1.12 (95%CI: 
1.03, 1.22).  Children whose asthma status was recorded before the age of 2 had an overall pooled 
aOR of 1.18 [95%CI:1.13,1.23] while children between the ages of 2 and 10 years had a pooled aOR 
of 1.13[95%CI:1.01, 1.26].  For studies that did a follow-up among children under the age of 2 years, 
subgroup analyses of acetaminophen exposure during different stages of pregnancy displayed 
consistent statistically significant associations between prenatal acetaminophen use and childhood 
asthma. The subgroup analysis of different stages of pregnancy for studies that reported asthma 
outcome among children older than 2 years of age showed that risk of childhood asthma was only 
associated with intrauterine exposure to  acetaminophen during the later stages of pregnancy 
(aOR[95%CI]: 1.23[1.08, 1.42]).  There was not enough information to verify a dose-response 
relationship. 
Conclusions: The findings support a modest association of exposure to prenatal acetaminophen 
use with childhood asthma development. By reviewing only prospective studies, we established 
temporality, thus further strengthening our hypothesis that acetaminophen use during pregnancy 
causes an increased risk of childhood asthma.  Further studies need to be conducted to confirm this 
association, and specify the dose, frequency and trimester use of acetaminophen. 
(Word count 398) 
Background 
Asthma is a chronic inflammatory airway disorder that affects approximately 9 million 
children in the United States (1).  It is caused by both genetic and environmental risk factors, and is 
characterized by bronchoconstriction, which is the tightening of muscles surrounding the 
bronchioles, inflammation and thickening as well as excessive mucous production of the airway 
walls, and hyperresponsiveness to triggers such as allergens and air pollution (2, 4). Common 
symptoms among asthmatic children include chest tightness, shortness of breath, wheezing and 
coughing (2).  These symptoms can lead to hospitalizations, ER visits, and school absences if the 
disease is not managed. The severity of one’s asthma condition ranges widely depending on the 
individual, environmental exposure, and the level of asthma management (2).  Although it cannot 
be cured, it can be controlled by careful management of the disease including the use of short acting 
beta2-agonists and long-term control medicines (2).  
Decreasing the prevalence of asthma or even the severity of asthma among children has 
important public health implications since childhood asthma is the most common chronic condition 
among children under the age of 18 (3).  Moreover, asthma is not just a problem within the U.S.  The 
World Health Organization recognizes it as a worldwide public health problem (4).  Because this 
chronic disease is often under-diagnosed, WHO’s estimation of 235 million people with asthma is 
most likely an underestimation (4). 
Mild analgesic over-the-counter (OTC) medication use is common during pregnancy (6, 7).  
It is known to reduce pain, fever, and inflammation. According to Werler et al, rates of mild 
analgesic use during pregnancy are higher than during the 3 months prior to pregnancy, suggesting 
that OTC drugs are used more during pregnancy (6). The top 10 medications that were taken in 
pregnancy, in rank order, were acetaminophen (aka paracetamol), ibuprofen, pseudoephedrine, 
aspirin, naproxen, diphenhydramine, guaifenesin, albuterol, amoxicillin, and dextromethorphan (6). 
Other studies have also shown that acetaminophen is the most preferred and commonly used 
analgesic and pyretic drug among pregnant mothers (5-9) since it is not associated with teratogenic 
effects (8-11). One study approximates about two-thirds of pregnant mothers taking it at one point 
during their pregnancy (6).  
Within the past five decades, the increasing prevalence of acetaminophen use has paralleled 
the increasing prevalence of asthma among children and adults (5- 7, 12-16), causing several 
epidemiologists to question whether acetaminophen use poses a risk of asthma development. The 
suspected association between acetaminophen and asthma development began in 1998, when 
Varner et al. published one of the first studies, suggesting an epidemiological trend between 
increased analgesics consumption and increased prevalence in asthma. The authors noted that the 
rising asthma trend also coincided with the transition from aspirin to acetaminophen use, which 
was precipitated by the discovery of aspirin's association with Reye's syndrome (5). Two years 
later, Newson et al. supported this finding with an ecological analysis on multiple countries that 
showed a positive correlation between the amount of acetaminophen consumption and prevalence 
of asthma and other atopic conditions among both adults and children (13). Shaheen et al. also 
published a population based case-control study, which demonstrated an association between 
acetaminophen intake and asthma development in adults (17). In 2004, Barr et al. reported similar 
results among women enrolled in a prospective study (18), and Koniman et al. discovered similar 
results in a matched patient-sibling study in 2007 (12). In 2008, Beasley et al. reported a 
statistically significant association between acetaminophen use during first year of life and the 
development of asthma symptoms at the age of 6-7 years (19).  
Furthermore, there is epidemiologic evidence that suggests a positive association between 
intrauterine exposure to acetaminophen and the development of childhood asthma (20-25), 
including a recent systematic review that concluded that acetaminophen use during pregnancy 
increases the risk of childhood asthma (26). However, a recent rigorous prospective cohort study 
suggests otherwise (27).  Because both acetaminophen use during pregnancy and childhood asthma 
are common, with asthma being a multi-factorial complex disease and acetaminophen being used 
for several purposes, it has been challenging to confirm an association between prenatal 
acetaminophen use and the risk of childhood asthma. Evidence of true association between 
intrauterine exposure to acetaminophen and childhood development of asthma would have 
important public health implications for pregnant women since acetaminophen is the 
recommended pain-reliever and fever-reducer during pregnancy, and currently about two-thirds of 
pregnant women take acetaminophen at some point during their pregnancy.    
Our study conducted a more rigorous systematic review and meta-analysis in an attempt to 
further clarify if prenatal acetaminophen is associated with physician-diagnosed childhood 
asthma.  Specifically, it addressed the question, "Among pregnant women, does acetaminophen use 
compared with non-use increase the risk for physician-diagnosed asthma before the age of 10?"  An 
overall analysis was conducted prior to performing a pre-specified subgroup analysis, which 
included age of child at diagnosis and stages of pregnancy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
Search Methods For Identification of Studies  and Study Selection Criteria  
PubMed search between the date of index start 1950 and December 1, 2011 was performed 
to identify prospective cohort studies that examined the association between intrauterine exposure 
to acetaminophen and asthma development during childhood. The search was restricted to English 
language and human studies only. The following query string was used: 
(acetaminophen[Title/Abstract] OR paracetamol[Title/Abstract] OR tylenol[Title/Abstract]) AND 
(asthma[Title/Abstract] OR wheez*[Title/Abstract]) AND (pregn*[Title/Abstract] OR 
child*[Title/Abstract] OR prenatal[Title/Abstract]). 
The primary exposure of interest was acetaminophen (paracetamol) intake during 
pregnancy (all trimesters included), and the primary outcome of interest was either physician-
diagnosed asthma or at least two symptoms (e.g. wheezing, emergency room visits, medication use 
for asthma, etc) that suggest asthmatic condition among children younger than or at 10 years of 
age.  Studies were included based on the following criteria: 1) The study design was a prospective 
cohort, 2) the primary exposure of interest was recorded 3) the primary outcome of interest was 
recorded. Conversely, studies were excluded based on the following criteria: 1) The study design 
was retrospective, cross-sectional, case-control, case series, or a case report, 2) the publication was 
a review, guideline, or editorial, 3) the study was only available in abstract form 4) the study did not 
have a clearly defined exposure or outcome, 5) "wheezing" was the only asthma-related outcome, 
6) the study did not assess asthma prior to 10 years of age, 7) there was a lack of a reported 
statistical measure of the association. 
Searches were performed by one reviewer. Titles and then abstracts were evaluated and 
rejected on initial screen based on the inclusion and exclusion criteria. Reference lists were also 
reviewed for relevant studies. Each study included was scored, using the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) checklist, and studies were excluded 
if they had <50% of STROBE checklist criteria.  The Meta-analyses of Observational Studies in 
Epidemiology (MOOSE) guidelines for conducting and reporting meta-analysis of observational 
studies were also utilized. Study investigators were contacted if additional information or data was 
required. 
Data extraction and management   
Data was extracted by one reviewer. The following values were extracted: authors' names, 
study design, year of publication, sample size, average age of children, confounders that were 
controlled for, estimated effect measure (preferably adjusted OR or adjusted RR), trimester, dose 
and frequency of acetaminophen intake, number of children with asthma, number of women who 
took acetaminophen during pregnancy.  
Statistical significance at α level of 0.05 (or at 95%CI) for pooled estimates was calculated 
using Review Manager (Revman) 5.1 (Cochrane Collaboration, Oxford, United Kingdom 
[http://ims.cochrane.org/revman]). The inverse-variance fixed-effects model was used for meta-
analysis calculation. Depending on the study, odds ratios or relative risks were recorded with 
adjusted estimates taken preference over unadjusted estimates. These estimates were entered into 
RevMan under the "Generic inverse variance" methodology for meta-analysis. Revman 
automatically calculates the natural logarithm estimates and their standard errors. With these 
calculations, RevMan produced a weighted average weight, utilizing the equation, 
ΣYi(1/SEi2)/Σ(1/SEi2), where Yi is the intervention effect estimated in the ith study, SEi is the 
standard error of that estimate, and the summation is across all studies (Cochrane Handbook, 
9.4.3).     
Heterogeneity was assessed using the I-squared statistic with low heterogeneity considered 
as <50%, moderate heterogeneity between 50- 75%, and high heterogeneity >75%. Meta-analysis 
was not conducted if heterogeneity was high.  Since the I-squared statistic showed low to moderate 
heterogeneity (<75%), sensitivity analysis was not performed to address heterogeneity problems. 
Publication bias was assessed using funnel plots. Other potential biases included information bias 
(e.g. recall bias) and selection bias due to attrition bias. Although it is difficult to detect information 
bias, attrition bias was assessed by observing the response rate. Subgroup analyses stratified by 
trimesters of exposure and age of diagnosis were also conducted. Sensitivity analysis was 
performed to test any assumptions or decisions we encountered when creating the subgroups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Study Selection    
The outcome of the literature review is shown in Figure 1. Eighty-five citations were 
initially identified in the electronic search.  Seventy-five studies were excluded after screening titles 
and abstracts, and out of the ten potentially eligible prospective studies, only six of them met the 
inclusion criteria after thorough review of the articles. Two studies were excluded because the 
outcome studied did not qualify for inclusion criteria; both assessed wheezing as the only outcome 
(30, 31).  The other two studies were excluded since both studies extracted data from a previously 
published study that was already included in this review (32, 33).  The six studies that were 
included in the review were all prospective studies, conducted during 2005~ 2010 across various 
countries including the US, UK, Denmark, Norway and Sweden (Table 1; see Appendix I for more 
details).   
Bakkeheim et al. used a group of participants from a 10-year follow-up prospective birth 
cohort, Environment and Childhood Asthma, in Oslo, Norway (34).  1,016 mothers were enrolled and 
assessed for acetaminophen exposure with the use of a questionnaire throughout all three 
trimesters and during the first 6 months since birth.  A structured interview followed by a clinical 
examination including pulmonary function tests, exercise test, skin prick test and blood test were 
performed for each child at the age of 10 years. The primary outcomes were history of asthma and 
symptoms and/or medication within the last year and/or positive exercise test. History of asthma 
was defined as having at least 2 of the following criteria: physician-diagnosed asthma; dyspnea, 
chest tightness and/or wheezing; and use of asthma medications.   
Goksor et al. reported data from a prospective study consisting of 4, 496 participants in 
Sweden (35). Prenatal acetaminophen exposure was obtained from a questionnaire that was given 
when the child was 6 months of age.  Because of the timing of the questionnaire, there is a 
possibility of recall bias as it is possible for children to be diagnosed with asthma by the age of 6-
months.  Supplemental data such as gender, gestational age, etc were also obtained from Swedish 
Medical Birth Records.  ‘Inhaled corticosteroids (ICS)-treated wheeze’ was used as a proxy for 
physician-diagnosed asthma at the age of 4.5 years. Recurrent wheeze and episodic viral wheeze 
were also recorded as separate outcomes.  
Kang et al. recruited 1,505 pregnant mothers in southern New England, U.S. and followed 
their children until the age of 6 years for physician-diagnosed asthma (27).  Intrauterine 
acetaminophen exposure (trimester, frequency and dose) was assessed through structured 
interviews during first trimester of pregnancy, and postpartum (to assess for exposure during last 
trimester of pregnancy). Secondary outcomes included wheezing, bronchitis, and allergy, with the 
primary outcome being physician-diagnosed asthma ever with history of wheezing at age 6 years. 
Persky et al. prospectively studied 345 pregnant women and their children who were 
enrolled in a randomized controlled trial that assessed the effects of home visits by community 
health educators and asthma-triggering environmental exposures in households (36).  Pregnant 
women participating in this study were enrolled and given a structured interview during their first 
trimester. At age 1, children were assessed for the following outcomes: asthma diagnosis, 
occurrence of any wheeze, wheeze that disturbed sleep, cough that disturbed sleep, emergency 
department visits for respiratory problems, and hospitalization secondary to respiratory 
problems. This study was conducted in Chicago, United States.  
Rebordosa et al. followed 66,445 pregnant women and their children from the Danish 
National Birth Cohort (37).  One baseline questionnaire was given at enrollment, along with two 
phone interviews during pregnancy, one parental phone interview when the child was 18 months 
of age, and a final parental phone interview and questionnaire at the age of 7.  In total, 66,445 
children at age 18 months were interviewed and 12,733 children at age 7 years were interviewed.  
The trimester, frequency and dose (only 2nd and 3rd trimester) of acetaminophen exposure were 
recorded through a computerized telephone interview, which was given during gestational weeks 
12 and 30, and respiratory outcomes were physician-diagnosed asthma, wheezing and 
hospitalization due to asthma. Some of the data was also extracted from the participants’ unique 
civil registration number, which is linked to the Danish National Hospital Registry.  
Shaheen et al. utilized the population-based Avon Longitudinal Study of Parents and 
Children in the county of Avon, England to study 8,511 pregnant women and their children (38). 
Bristol district-residing women were eligible if their expected date of delivery fell within the time 
frame of April 1, 1991 and December 31, 1992.  Acetaminophen intake during pregnancy (both 
trimester and frequency) was obtained from a questionnaire that was given during 18-20 weeks of 
pregnancy and again at 32 weeks of pregnancy. Outcomes that were assessed when the child was 
81 months old were the following: physician-diagnosed asthma, frequency of wheezing, hay fever, 
eczema and atopy.   
Table 2 displays the prevalence of intrauterine exposure to acetaminophen by studies.  The 
prevalence ranges widely from 3% to 70% with Bakkeheim et al. and Goksor et al. having the 
lowest prevalence of 3% and 7.7%, respectively and the others having prevalences greater than 
45%.   
All six studies controlled for various confounders (Table 3).  They calculated adjusted odds 
ratio measurements with the exception of Bakkenheim et al. who presented their estimates as 
unadjusted ORs, and Reberdosa et al. who presented their adjusted estimate measurements as 
adjusted relative risks.  While Goksor et al., Reberdosa et al. and Shaheen et al. found a statistically 
significant association between prenatal acetaminophen intake and risk of childhood asthma, 
Persky et al., Bakkenheim et al. and Kang et al. reported null results.  Moreover, Kang et al. 
suggested a protective effect when acetaminophen is ingested during both first and second 
trimester of pregnancy [aOR(95%CI):  0.59(0.36, 0.98)].  
Lastly, the review identified any study that included multiple children from the same 
mother as independent enrollments and/or twins. Kang et al. excluded women from the analysis if 
they had multiple births during the study enrollment period (April 1997- June 2000). Neither 
Goksor et al. nor Persky et al. specified their method of adjusting for multiple births and twins. 
Reberdosa et al. required that women give births to singletons, but did not address the issue of 
multiple births. And both Shaheen et al. and Reberdosa et al. had a one year enrollment period, 
which eliminated the possibility of multiple births from a single mother. However, they did not 
address the concern of twins. 
Estimated Effect Measurements 
The pooled fixed-effects OR for all six studies was 1.12 (1.03, 1.22), (Fig. 2).  Three studies 
presented ORs within the stratified groups, but did not present the overall effect (33, 34, 37).  Both 
Shaheen et al. and Bakkeheim et al. calculated ORs for the different pregnancy stages of 
acetaminophen exposure (0-20 weeks of pregnancy and 20-32 weeks of pregnancy; 1st and 2nd/3rd 
trimesters, respectively).  For both studies, the two pregnancy stages could not be collapsed into 
one group since women who took acetaminophen throughout their entire pregnancy would be 
accounted for twice.  Consequently, we could not calculate the overall effect that acetaminophen 
exposure during any period of pregnancy had on childhood asthma. Sensitivity analyses 
demonstrated that while either of the two pregnancy groups in Bakkeheim et al.’s groups produced 
the same overall pooled fixed-effects OR calculation for the six studies, Shaheen et al.’s ORs from the 
two pregnancy stages produced slightly different pooled estimates. When we included Shaheen et 
al.’s OR from the “0-20 weeks of pregnancy” group, we calculated the previously stated pooled 
fixed-effects OR of 1.12 (1.03, 1.22).  When we used the OR from the “20-32 weeks of pregnancy” 
instead, we concluded with a pooled fixed-effects OR of 1.17 (1.07, 1.27).  Finally, Reberdosa et al. 
published two aORs that revealed the association between acetaminophen exposure during any 
time of pregnancy and the risk of childhood development of asthma at ages 18 months and 7 years.  
Instead of doing a sensitivity analysis, we used the OR from the group that was diagnosed with 
asthma at 7 years of age since it is difficult to diagnose asthma among children under 6 (39).   
The meta-analysis was stratified into studies that examined children under the age of 2 
years and studies that diagnosed asthma in children over the age of 2.  The age cut-off of 2 years 
was selected as there was a clear division between two studies that assessed asthma in children at 
ages 1 year and 18 months, and the rest of the studies that focused on children between the ages 
4.5 years and 7 years.  Reberdosa et al. conducted a longitudinal follow-up on children at ages 18 
months and 7 years, and these two outcomes were analyzed separately.   
Acetaminophen use during any stage of the entire pregnancy significantly increased the risk 
of asthma in children under the age of 2 years, with a pooled fixed-effects OR of 1.18 (95%CI: 1.13, 
1.23) (Fig. 3a).  The subgroup analysis of acetaminophen intake during different trimesters showed 
that acetaminophen intake during any one trimester was significantly associated with an increased 
risk of asthma development in children (Fig. 3b).  However, Persky et al.’s study reported a 
statistically insignificant association between acetaminophen intake during 2nd and 3rd trimester 
and childhood asthma.  Intrauterine acetaminophen exposure during the first trimester of 
pregnancy produced a statistically significant pooled OR of 1.15 (95%CI: 1.10, 1.20).  Similarly 
exposure during the second trimester of pregnancy resulted in a pooled OR of 1.13 (95%CI: 1.09, 
1.17), and exposure during the third trimester of pregnancy resulted in a pooled OR of 1.17 (95%CI: 
1.13, 1.21).  
Acetaminophen use during any stage of the entire pregnancy significantly increased the risk 
of asthma in children between ages 2- 10 years, with a pooled fixed-effects OR of 1.13 (95%CI: 1.01, 
1.26) (Fig. 4a).  The stratified analysis of acetaminophen intake during different stages of pregnancy 
produced mixed results (Fig. 4b).  There were no significant associations between acetaminophen 
intake during the first two trimesters of pregnancy and asthma in offsprings.  However, 
acetaminophen intake during medium to late stages of pregnancy (a combination of 2nd and 3rd 
trimester or 20-32 weeks of pregnancy) significantly increased the risk of asthma in children by 
23% (pooled OR and 95%CI of 1.23[1.08, 1.42]).  Lastly, intrauterine acetaminophen exposure 
during the third trimester of pregnancy produced a statistically significant pooled OR of 1.16 
(95%CI: 1.03, 1.30).   
There was no evidence of high heterogeneity among the studies.  The majority of I2 
calculations resulted in 0% with the exception of I2= 31% in the overall pooled estimate of the six 
studies, and 71% in the overall pooled estimate for asthma outcome in children over 2 years of age.   
A variety of biases were noted (see Appendix I for more details). Because most of these 
studies relied on self-report, incomplete ascertainment of exposure and outcome may have caused 
information bias.  However, recall bias was minimized by interviewing pregnant women during 
pregnancy when the asthma outcome was yet to be determined, and the acetaminophen intake can 
be more accurately reported.  Detection bias was minimized by using physician-diagnosed asthma 
as the primary outcome of interest.  Selection bias due to attrition bias may have been a concern for 
some of these studies as non-participants were noted to be different from the participants (Goksor 
et al. 2011). Specifically, those who did not participate tended to smoke before pregnancy, have 
preterm birth and have lower education. Even after stratifying the meta-analysis by study qualities 
by excluding Goksor et al’s study, we concluded with a significant association of acetaminophen 
ingestion during pregnancy and the risk of developing asthma during childhood years (OR[95%CI]: 
1.10[1.01, 1.20]).  
Lastly, in terms of publication bias, the funnel plot (Fig. 5) demonstrated a normal trend, 
with findings from studies with smaller sample sizes found dispersed at the bottom of the funnel 
and results from studies with larger sample sizes located toward the top of the funnel in the high 
precision area.  The plot indicated a slight trend to the right of the reference line, suggesting that 
studies with insignificant or protective association were missing.   
 
 
 
 
 
 
Discussion 
Acetaminophen has been considered the preferred choice of over-the-counter pain-reliever 
and fever-reducer medication during pregnancy (5-11, 44-47).  It is labeled as FDA Category B 
across all trimesters, indicating that animal studies have not demonstrated any fetal risk or if it has, 
there have been no randomized controlled studies among pregnant women to prove this finding 
(47).  Guidelines for medication use during pregnancy have recommended using acetaminophen 
minimally and only when necessary (44-46).  Pregnant women should follow the dosage 
instructions on the back of the medication package, and ingestion of acetaminophen should not 
exceed the recommended dose of 4 grams a day (44- 46).  Currently, we do not know how much 
acetaminophen crosses the placenta.  
Overall, prenatal acetaminophen exposure increases the risk of childhood asthma 
development with a pooled fixed-effects OR (95 CI%) of 1.12 (1.03, 1.22).  The studies were 
subgrouped by age of asthma diagnosis (≤ 2 years vs. >2 years) as clinical diagnosis of asthma have 
been reported to be more accurate as the child nears 6 years of age (39). The pooled fixed-effects 
ORs for both subgroups were consistent with the overall estimate, with the subgroup estimates 
being 1.13 (1.01, 1.26) and 1.18 (1.13, 1.23) for children being diagnosed with asthma at ages 2 
years and above and less than 2 years, respectively.   
These results are consistent with past reviews conducted by Etiman et al. and Eyers et al. 
(26, 29).  Etiman et al. (2009) had conducted a larger systematic review, which consisted of studies 
that investigated acetaminophen exposure during pregnancy, childhood years, and adult years.  
Although Etiman et al. demonstrated an association between acetaminophen use during pregnancy 
and increased risk of childhood asthma with an OR (95%CI) of 1.28 (1.13-1.39), Eyers et al. (2011) 
argued that there were several methodological problems.  For instance, the outcome was not 
standardized across all studies and the details necessary to assess the validity of this systematic 
review were missing (29).  Additionally, Etiman et al.’s systematic review was not focused solely on 
prenatal acetaminophen use and risk of childhood asthma (29).  Lastly, one of the ORs reported in 
Etiman et al.’s paper is nowhere to be found in the original paper, and Etiman et al. used hazards 
ratio  for “hospitalization for asthma” instead of relative risk for “physician-diagnosed asthma” for 
one of the selected studies (Reberdosa et al. 2008) (Table 4).   
For the reasons stated above, Eyers et al. (2011) conducted a systematic review and meta-
analysis, and concluded that acetaminophen use during pregnancy remained a risk factor for 
childhood asthma development. However, there were several methodological limitations. First, only 
studies that provided raw data were included in the review as the pooled summary estimate was 
calculated utilizing unadjusted odds ratios from the raw data. Consequently, the authors neglected 
to take into account confounders such as parental history of asthma, maternal age, antibiotic use, 
smoking and alcohol status and child's gender. Additionally, by restricting studies to those that 
provide raw data, the authors may have overlooked studies that may have otherwise qualified for 
inclusion. Second, the authors defined 'wheeze in the past 12 months' as the primary outcome of 
interest. The condition 'wheezing' is subjective to individual interpretation and may not accurately 
capture those with asthma. Furthermore, this outcome may have included non-asthmatic children, 
thereby overestimating the number of cases. Lastly, the inclusion criteria included a range of 
observational studies, resulting in the inclusion of both prospective and cross-sectional studies. 
This combination may have weakened the conclusion that would have been more viable if cross 
sectional studies were removed from the review. Unlike prospective cohort studies, cross-sectional 
studies do not establish temporality.  Consequently, cross-sectional studies cannot establish 
evidence of causality between acetaminophen use and risk of asthma development.  
Table 4 compares and contrasts the studies that were selected for analysis in Eyers et al., 
Etiman et al. and this systematic review.  Three out of the total six studies from Eyers et al.’s review 
were included in the current review. However, this review utilized the adjusted OR while Eyers et 
al. calculated the unadjusted OR from the raw data.  Although three out of the total five studies from 
Etiman et al.’s review were used, two of the estimates did not coincide with this review’s ORs.  
While Etiman et al. recorded the hazard ratio for “hospitalization for asthma” from Reberdosa et 
al.’s study, this review retrieved the relative risk for “physician-diagnosed asthma”.  Also, Etiman et 
al.’s OR from Shaheen et al.’s study was nowhere to be located in the original publication.   
This meta-analysis showed a significant positive association between acetaminophen intake 
during the later stages of pregnancy and risk of asthma diagnosis at ages 2 years and older.  
Meanwhile, studies that recorded asthma outcome in children younger than 2 years of age 
displayed an increased risk of childhood asthma when acetaminophen was ingested during any 
trimester of one’s pregnancy.  More studies need to be conducted to compare the different 
trimesters to assess which trimester(s) produces the highest risk of childhood asthma.  
There was surprisingly a wide range of prenatal acetaminophen-use prevalence rates 
among the six studies.  Although Bakkeheim et al. had a high response rate of 99.7%, the low 
prevalence rate of acetaminophen use of 3% may have been due to information bias since mothers 
were asked to recall their acetaminophen use during pregnancy when their child turned 6 months 
old. Consequently, it is possible that mothers underreported their exposure to prenatal 
acetaminophen use.  Goksor et al. also had a low prevalence rate of 7.7%, however, this can be 
explained by the low response rate of 55%, which caused selection bias.  Goksor et al. reported that 
non-responders tended to smoke during pregnancy, have preterm birth and have lower education 
level.  To determine if these two studies invalidated the pooled fixed-effects OR of 1.12 (1.03, 1.22), 
sensitivity analysis was conducted.  Excluding these two studies from the pooled fixed-effects OR 
did not change the result as the newly calculated estimate was 1.10 (1.01, 1.20) when the OR from 
Shaheen et al.’s “1-20 weeks of pregnancy” group was used, and 1.16 (1.06, 1.26) when the OR from 
Shaheen et al.’s “20-32 weeks of pregnancy” group was used.   The other five studies have 
prevalence rates that were reasonably proximal to 66%, which was the recorded rate by a previous 
study (6).     
 This meta-analysis has several strengths.  First, we used a more stringent exposure and 
outcome inclusion criteria for study selection compared to previous systematic reviews.  We 
narrowed our search to prospective studies, and we only included studies that reported physician-
diagnosed asthma or two of the three asthma conditions as outcomes.  Second, unlike previous 
meta-analyses, we took preference of adjusted estimates over unadjusted estimates when 
calculating the pooled inverse variance fixed-effects OR.  Third, all six studies had rigorous study 
designs such that biases were minimized.  Additionally, by looking into prenatal exposure to 
acetaminophen, we were able to negate the possibility of reverse causality, which is a common 
problem for studies that investigated the association between postnatal acetaminophen intake and 
risk of asthma development.  In reverse causality, it is difficult to prove the causality between 
acetaminophen intake and asthma since those with asthma may be more likely to ingest 
acetaminophen due to increased co-morbidities such as respiratory infections and headaches (40-
43). Fourth, our meta-analysis had low heterogeneity, allowing us to use fixed-effects to calculate 
pooled estimates. Lastly, since Eyers et al.’s publication, one new study has been published and 
included in this review.   
 Our study also has limitations. First, this systematic review did not look into randomized 
controlled studies. However, randomized controlled studies that investigate the association of 
prenatal acetaminophen use of risk of childhood asthma do not exist due to ethical reasons.  
Consequently, we chose to review prospective cohort studies, which are the next preferred study 
design.  Second, we were unable to stratify the reported estimates by confounders as each study 
adjusted for varying combination of confounders.  Third, as with any study, there is a possibility of 
residual confounding.  For example, the reasons for ingesting acetaminophen during pregnancy 
may be a confounder as mothers who have asthma may potentially be taking acetaminophen for 
their asthma.  Despite these limitations, we used a sound and rigorous methodology under the 
condition given to us (e.g. RCTs not being available, studies adjusting for different confounders, 
etc.). 
 In conclusion, this systematic review and meta-analysis supports previous studies and 
meta-analyses (26, 29) that have reported an association between prenatal acetaminophen 
exposure and increased risk of childhood asthma.  Although Eyers et al. reported an increased risk 
of childhood asthma due to prenatal acetaminophen use, an editorial on Eyers et al.’s findings 
concluded “for the time being, there is no need to recommend any changes to the clinical practice” 
(48).  This review revisits this topic and underscores the importance of further investigation as this 
review suggests that intrauterine acetaminophen exposure increases the risk of childhood asthma 
by approximately 12%- 17%. This result has significant clinical implications as more than half of 
pregnant women ingest acetaminophen, and asthma is the most prevalent chronic illness among 
children.  Future studies that look into the timing of acetaminophen intake during pregnancy will 
further help mothers time their acetaminophen intake during pregnancy.  Moreover, it would be 
beneficial if studies investigate how frequency and dose of acetaminophen use during pregnancy 
affects the risk of childhood asthma.  
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Figure 1: Flow Chart for Identifying Studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Basic Characteristics of Included Studies 
Study 
Publication 
Year 
Country Population 
Acetaminophen 
Dose/Frequency 
Bakkeheim et al. 2010 Norway Children 10 yrs No 
Goksor et al. 2011 Sweden Children 4.5 yrs No 
Kang et al. 2009 US Children 6 yrs Dose a and Frequency b 
Persky et al. 2008 US Children 1 yr No 
Reberdosa et al. 2008 Denmark 
Children 18 mo and 7 
yrs 
Dose c and Frequency d 
Shaheen et al. 2005 UK Children 6-7 yrs Frequency e 
a) # of tablets or doses of acetaminophen per day in a month 
b) “none”, “1-7 days per month”, “8-14 days per month”, “more than 14 days (but not every day) per month”, and 
“everyday” 
c) Only for 2nd and 3rd trimester 
d) Total # of weeks of acetaminophen exposure per trimester 
e)  “not at all”, “sometimes”, “most days”, “everyday” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Prevalence of intrauterine exposure to acetaminophen by studies 
Study 
Percent of 
mothers taking 
acetaminophen 
during pregnancy 
Bakkeheim et al. 3.0 
Goksor et al. 7.7 
Kang et al. 69.0 
Persky et al. 70.0 
Reberdosa et al. 53.9 
Shaheen et al. 46.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Estimates of Included Studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Meta-analysis of all six studies  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
Shaheen et al. 2005 (1)
Rebordosa et al. 2008 (2)
Persky et al. 2008
Kang et al. 2009
Goksor et al. 2011
Bakkeheim et al. 2010 (3)
Total (95% CI)
Heterogeneity: Chi² = 7.28, df = 5 (P = 0.20); I² = 31%
Test for overall effect: Z = 2.55 (P = 0.01)
log[Odds Ratio]
0.0953
0.1398
0.47
-0.2744
0.47
0.0392
SE
0.0695
0.0612
0.7073
0.1839
0.2347
0.5004
Weight
39.2%
50.6%
0.4%
5.6%
3.4%
0.8%
100.0%
IV, Fixed, 95% CI
1.10 [0.96, 1.26]
1.15 [1.02, 1.30]
1.60 [0.40, 6.40]
0.76 [0.53, 1.09]
1.60 [1.01, 2.53]
1.04 [0.39, 2.77]
1.12 [1.03, 1.22]
Odds Ratio
(1) 0-20 weeks of pregnancy; Pooled estimate was 1.17(1.07, 1.27) when 20-32 weeks of pregnancy was used instead.
(2) Children 7 years of age
(3) First trimester of pregnancy; The pooled estimate was the same even when the group, 2nd/3rd trimesters of pregnancy, was used instead.
Odds Ratio
IV, Fixed, 95% CI
0.2 0.5 1 2 5
Favours experimental Favours control
Figure 3: Meta-analysis of studies that diagnosed asthma in children < 2 years of age: 
 
Figure 3a: Exposure during entire pregnancy  
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
Persky et al. 2008
Rebordosa et al. 2008
Total (95% CI)
Heterogeneity: Chi² = 0.19, df = 1 (P = 0.67); I² = 0%
Test for overall effect: Z = 7.51 (P < 0.00001)
log[Odds Ratio]
0.47
0.1655
SE
0.7073
0.0221
Weight
0.1%
99.9%
100.0%
IV, Fixed, 95% CI
1.60 [0.40, 6.40]
1.18 [1.13, 1.23]
1.18 [1.13, 1.23]
Odds Ratio Odds Ratio
IV, Fixed, 95% CI
0.2 0.5 1 2 5
Favours experimental Favours control
 
Figure 3b: Exposure during different periods of pregnancy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
2.4.1 Early pregnancy (1st trimester)
Persky et al. 2008
Rebordosa et al. 2008
Subtotal (95% CI)
Heterogeneity: Chi² = 0.06, df = 1 (P = 0.80); I² = 0%
Test for overall effect: Z = 6.18 (P < 0.00001)
2.4.2 Medium pregnancy (2nd trimester)
Rebordosa et al. 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 6.64 (P < 0.00001)
2.4.3 Medium to late pregnancy (2nd/3rd trimesters)
Persky et al. 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
2.4.4 Late pregnancy (3rd trimester)
Rebordosa et al. 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 8.87 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 2.73, df = 4 (P = 0.60); I² = 0%
Test for overall effect: Z = 12.63 (P < 0.00001)
Test for subgroup differences: Chi² = 2.67, df = 3 (P = 0.45), I² = 0%
log[Odds Ratio]
0.2624
0.1398
0.1222
0.6931
0.157
SE
0.4875
0.0227
0.0184
0.6143
0.0177
Weight
0.1%
24.0%
24.0%
36.5%
36.5%
0.0%
0.0%
39.4%
39.4%
100.0%
IV, Fixed, 95% CI
1.30 [0.50, 3.38]
1.15 [1.10, 1.20]
1.15 [1.10, 1.20]
1.13 [1.09, 1.17]
1.13 [1.09, 1.17]
2.00 [0.60, 6.67]
2.00 [0.60, 6.67]
1.17 [1.13, 1.21]
1.17 [1.13, 1.21]
1.15 [1.13, 1.18]
Odds Ratio Odds Ratio
IV, Fixed, 95% CI
0.2 0.5 1 2 5
Favours experimental Favours control
Figure 4: Meta-analysis of studies that diagnosed asthma in children > 2 years of age: 
 
 
Figure 4a: Exposure during entire pregnancy  
 
Study or Subgroup
Goksor et al. 2011
Kang et al. 2009
Rebordosa et al. 2008
Total (95% CI)
Heterogeneity: Chi² = 6.93, df = 2 (P = 0.03); I² = 71%
Test for overall effect: Z = 2.13 (P = 0.03)
log[Odds Ratio]
0.47
-0.2744
0.1398
SE
0.2347
0.1839
0.0612
Weight
5.8%
9.4%
84.8%
100.0%
IV, Fixed, 95% CI
1.60 [1.01, 2.53]
0.76 [0.53, 1.09]
1.15 [1.02, 1.30]
1.13 [1.01, 1.26]
Odds Ratio Odds Ratio
IV, Fixed, 95% CI
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Figure 4b: Exposure during different periods of pregnancy 
 
 
 
 
 
Study or Subgroup
1.3.1 Early pregnancy (1st trimester)
Bakkeheim et al. 2010
Kang et al. 2009
Rebordosa et al. 2008
Subtotal (95% CI)
Heterogeneity: Chi² = 3.28, df = 2 (P = 0.19); I² = 39%
Test for overall effect: Z = 1.74 (P = 0.08)
1.3.2 Early to medium pregnancy (0-20 weeks)
Shaheen et al. 2005
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
1.3.3 Medium pregnancy (2nd trimester)
Rebordosa et al. 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
1.3.4 Medium to late pregnancy (2/3 trimesters or 20-32 weeks)
Bakkeheim et al. 2010
Shaheen et al. 2005
Subtotal (95% CI)
Heterogeneity: Chi² = 0.19, df = 1 (P = 0.67); I² = 0%
Test for overall effect: Z = 3.02 (P = 0.003)
1.3.5 Late pregnancy (3rd trimester)
Kang et al. 2009
Rebordosa et al. 2008
Subtotal (95% CI)
Heterogeneity: Chi² = 0.57, df = 1 (P = 0.45); I² = 0%
Test for overall effect: Z = 2.52 (P = 0.01)
Total (95% CI)
Heterogeneity: Chi² = 6.78, df = 8 (P = 0.56); I² = 0%
Test for overall effect: Z = 4.28 (P < 0.0001)
Test for subgroup differences: Chi² = 2.75, df = 4 (P = 0.60), I² = 0%
log[Odds Ratio]
0.0392
-0.3857
0.1398
0.0953
0.0583
0
0.2151
-0.0943
0.157
SE
0.5004
0.2837
0.0662
0.0695
0.0723
0.4937
0.0705
0.3264
0.0601
Weight
0.4%
1.1%
20.1%
21.6%
18.2%
18.2%
16.9%
16.9%
0.4%
17.7%
18.1%
0.8%
24.4%
25.2%
100.0%
IV, Fixed, 95% CI
1.04 [0.39, 2.77]
0.68 [0.39, 1.19]
1.15 [1.01, 1.31]
1.12 [0.99, 1.27]
1.10 [0.96, 1.26]
1.10 [0.96, 1.26]
1.06 [0.92, 1.22]
1.06 [0.92, 1.22]
1.00 [0.38, 2.63]
1.24 [1.08, 1.42]
1.23 [1.08, 1.42]
0.91 [0.48, 1.73]
1.17 [1.04, 1.32]
1.16 [1.03, 1.30]
1.14 [1.07, 1.20]
Odds Ratio Odds Ratio
IV, Fixed, 95% CI
0.2 0.5 1 2 5
Favours experimental Favours control
 
Figure 5: Funnel plot of comparison: Prenatal acetaminophen use during entire pregnancy 
(Children diagnosed with asthma >2 years of age). 
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Early pregnancy (1st trimester)
Early to medium pregnancy (0-20 weeks)
Medium pregnancy (2nd trimester)
Medium to late pregnancy (2/3 trimesters or 20-32 weeks)
Late pregnancy (3rd trimester)
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Table 4: Current vs. Past Systematic Reviews 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
Table I: Characteristics of Included Studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table II: Risk of Biases  
 
  
 
 
